C

Cresilon

Plant-based hemostatic gel for bleeding control

Production Technician 1

Full-TimeUpdated on 10/17/2026
$20 - $24/hr
Junior
Bachelor's
Brooklyn, NY, USA
In Person
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • High school diploma or equivalent with at least two years of relevant manufacturing experience in the pharmaceutical, biotechnology, or medical device industry, or a two- or four-year degree with no prior relevant experience.
  • Ability to read, understand, and execute written work instructions.
  • Ability to complete documentation accurately.
  • Ability to add, subtract, multiply, and divide in all units of measure using whole numbers, common fractions, and decimals.
  • Ability to become gowning qualified to work in a cleanroom environment.
  • Ability to problem solve and achieve business objectives.
  • Ability to adapt the training approach.
  • Proficiency in Microsoft Office, including Word, Excel, and Outlook.
  • Must be able to work overtime and/or second shift when needed.
Responsibilities
  • Perform line clearance of assigned production areas as required.
  • Perform equipment setup and disassembly activities.
  • Operate production, assembly, and testing equipment, including heat sealers, barcode scanners, weighing scales, tumblers, autoclaves, filling equipment, and packaging equipment.
  • Formulate, fill, and pouch products in accordance with standard operating procedures.
  • Troubleshoot operating deviations and issues and coordinate with other functions when required.
  • Report machine and operating deviations to the area supervisor or designee.
  • Perform routine preventative maintenance on equipment.
  • Clean and disinfect manufacturing spaces.
  • Clean and sterilize manufacturing equipment.
  • Perform visual inspection of components and/or products in accordance with standard operating procedures and current Good Manufacturing Practices.
  • Perform sampling and package intermediate and finished goods according to standard operating procedures.
  • Package and ship raw materials for sterilization.
  • Perform material receiving, staging, movements, and replenishment according to standard operating procedures.
  • Transport samples, materials, and equipment between multiple facilities.
  • Complete data entry and generate reports for material inventory movements.
  • Complete and maintain applicable logbooks and batch record paperwork in accordance with Good Manufacturing Practices and Good Documentation Practices.
  • Maintain a clean production environment during the shift.
  • Report actual, near-miss, and potential accidents for further investigation.
  • Take immediate action to resolve near-miss situations.
  • Assist in investigating actual, near-miss, and potential accidents; provide information to troubleshoot and take initiative to resolve operational issues independently.
  • Assist in project commissioning and validation activities as necessary.
  • Prepare samples or prototypes for testing or other evaluations as required.
  • Monitor plant status and liaise with colleagues in other departments to prevent interruptions to the manufacturing process.
  • Complete all required training, including Read and Understand, computer-based training with quiz, instructor-led training, and on-the-job training.
  • Oversee training of junior employees on production processes as assigned.
  • Ensure proper communication and handover of shift duties.
  • Support Environmental and Personnel Monitoring activities as directed.
  • Perform other duties as assigned and required.

About the company

Cresilon makes medical devices that stop bleeding with a plant-based adhesive gel. Its main product, VETIGEL, is a fast-acting gel designed to control bleeding in veterinary patients, and Cresilon serves human trauma and surgical markets as well. The gel is applied to a wound and works to seal and promote clotting within seconds without needing manual pressure. Cresilon differentiates itself by offering a gel-based hemostat and by being among the first to target veterinary applications with a rapid, easy-to-use solution, along with direct sales and partnerships (for example, the VerticalVet Preferred Partnership) to reach clinics and hospitals. The company’s goal is to broaden the gel technology’s uses to improve wound care and save lives across veterinary, human trauma, and surgical settings.

Company Size

51-200

Company Stage

Early VC

Total Funding

$116.5M

Headquarters

New York City, New York

Founded

2010

Get referred to Cresilon

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sept. 30, 2026 TRAUMAGEL Next Generation expanded use across EMS, tactical, and hospitals.
  • Aug. 4, 2025 Vizient gave TRAUMAGEL an Innovative Technology contract nationwide.
  • June 16, 2025 McCarthy Vet opened VETIGEL sales across Canada.

What critics are saying

  • Cresilon still depends on expensive clinician training to displace gauze, clamps, and legacy hemostats.
  • In 2025, Cresilon pulled a launch after field misses, proving execution risk.
  • TRAUMAGEL remains the revenue engine; procurement stalls threaten Cresilon's runway and valuation.

What makes Cresilon unique

  • Cresilon's plant-based hydrogel stops bleeding in seconds without manual pressure or preparation.
  • TRAUMAGEL's 2026 compact syringe enables one-handed EMS use and go-bag portability.
  • VETIGEL reached 60,000 procedures worldwide and VerticalVet opened access to 1,800 members.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Health Savings Account/Flexible Spending Account
  • Disability Insurance
  • Life Insurance
  • Commuter Benefits
  • 401(k) Company Match
  • Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

4%

2 year growth

3%
PR Newswire
Sep 30th, 2026
Cresilon launches compact TRAUMAGEL next-gen hemostatic gel for first responders

Brooklyn-based biotechnology company Cresilon has launched a next-generation version of its TRAUMAGEL hemostatic gel, debuting at EMS World Expo 2026 in Orlando, Florida. The new compact syringe format enables one-handed application whilst maintaining the same bleeding control technology as the original product. TRAUMAGEL is a plant-based gel that controls moderate to severe bleeding in seconds, requiring no preparation before use. The redesigned format offers a smaller footprint for tactical, prehospital and hospital settings, whilst the original version remains available. "When a trauma patient is severely bleeding, every second matters," said Joe Landolina, CEO and co-founder of Cresilon. Published clinical evidence documents successful hemorrhage control in complex traumatic injuries, with providers reporting faster application and quicker bleeding control.

The Mirror Democrat and Savanna Times-Journal
Mar 25th, 2026
Cresilon named one of the World's 50 Most Innovative Companies by Fast Company.

Cresilon named one of the World's 50 Most Innovative Companies by Fast Company. * 6 hrs ago PR Newswire NEW YORK, March 25, 2026 Ranked No. 1 in the medical devices category and No. 46 on Fast Company's World's 50 Most Innovative Companies list NEW YORK, March 25, 2026 /PRNewswire/ - Cresilon has been named to Fast Company's World's 50 Most Innovative Companies of 2026. The company ranked No. 1 in the medical devices category and No. 46 overall. This marks the second time Cresilon has earned the top spot in its category, after first being recognized in 2024. "Being named one of the World's 50 Most Innovative Companies and ranked No. 1 in medical devices again speaks to the work our team is doing every day," said Joe Landolina, co-founder and CEO of Cresilon. "We started Cresilon with a clear mission to save lives. Today, TRAUMAGEL is in the hands of first responders and trauma care providers across the country and making a real impact. This recognition reflects the progress we've made and the real-world impact our solution is having in trauma care." Since its last recognition, Cresilon has advanced its hemostatic technology and expanded its reach. TRAUMAGEL(R) received FDA clearance in August 2024 and launched nationwide in January 2025. Clinical use cases reported by critical care providers show TRAUMAGEL saved at least one life per day on average in 2025. The product is now used by first responders and hospitals across the U.S. to control bleeding quickly and help prevent death from severe blood loss, which accounts for more than 35% of prehospital deaths. By the end of 2025, TRAUMAGEL was in use across all targeted care settings, including law enforcement, fire, EMS, and hospital trauma teams. The product is also being evaluated by the U.S. military and has been fielded by select units. To support this growth, Cresilon expanded its manufacturing footprint to 55,000 square feet at its state-of-the-art biomanufacturing facility in Brooklyn. The World's Most Innovative Companies is Fast Company's hallmark franchise and one of its most anticipated editorial efforts of the year. This year's list highlights businesses shaping industry and culture through innovation. Alongside the World's 50 Most Innovative Companies, Fast Company also recognized 720 organizations across 59 sectors and regions. To determine honorees, Fast Company's editors and writers review companies driving progress across industries and regions. They evaluate thousands of submissions through a competitive process. The result is a global look at innovation, from early-stage startups to some of the most valuable companies in the world. "Our list of the Most Innovative Companies is about spotlighting organizations that don't just adapt to change. They drive it," said Brendan Vaughan, editor-in-chief of Fast Company. "The companies we honor this year are setting the pace for their industries and showing what sustained innovation can achieve." The full list of Fast Company's Most Innovative Companies honorees is available at fastcompany.com. It will also appear on newsstands beginning March 31, 2026. About Cresilon Cresilon(R) is a Brooklyn-based biotechnology company that develops, manufactures, and markets hemostatic medical devices using its proprietary hydrogel technology. The company's plant-based technology stops bleeding in seconds. Its current and future product lines target trauma care, biosurgery, and animal health. Cresilon's mission is to save lives. The company has been recognized by Fast Company as one of the World's 50 Most Innovative Companies and named an EMS World Innovation Awards winner for TRAUMAGEL. For more information, visit www.cresilon.com. SOURCE Cresilon

Industry City
Sep 10th, 2025
Park Slope biotech firm raises $17M after recent growth spurt

Cresilon raised $17 million in a late stage venture capital round following growth in both the company's footprint and distribution network in recent months.

Crain's New York Business
Sep 9th, 2025
Cresilon raises $17M after growth spurt

A Park Slope-based biotech startup, Cresilon, has raised $17 million in a late-stage venture capital round. This funding follows recent growth in the company's footprint and distribution network. It marks the third significant fundraising effort since Cresilon received FDA approval for its bleeding-stopping gel.

PR Newswire
Jun 16th, 2025
Cresilon Announces International Distribution Agreement For Vetigel With Mccarthy Vet

Revolutionary hemostatic gel for veterinary surgeons available in Canada through leading veterinary supply companyNEW YORK, June 16, 2025 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into a distribution agreement for VETIGEL® to be sold directly to veterinary surgeons in Canada through McCarthy Vet, a full-service veterinary marketing, supply and distribution company exclusively serving veterinarians in the Canadian animal health industry.VETIGEL, a revolutionary plant-based hemostatic gel that instantly stops and controls bleeding, is now available for veterinarian surgeons across Canada through McCarthy Vet. The agreement with McCarthy Vet, a family-owned and operated company that has exclusively served the Canadian veterinary community for over 60 years, is Cresilon's first veterinary distribution partnership in Canada."Our partnership with McCarthy Vet will help us provide more veterinary surgeons with an innovative hemostatic gel that significantly improves the standard of care for pets and animals," said VETIGEL National Sales Manager Brittany Boysen. "VETIGEL has been used by thousands of veterinarians around the world and helps veterinary clinics and animal hospitals save time, reduce operating costs, and improve patient outcomes."Since the product's debut in 2021, veterinary surgeons across North America, Europe, and Asia have increasingly used VETIGEL as the fastest and most effective hemostatic agent when treating animals for traumatic wounds and routine and complex surgical procedures, including dental extractions, liver biopsies, tumor and mass removals, cleft palate repairs, and amputations. To date, the plant-based hemostatic gel for veterinary surgeons has been used in more than 60,000 surgical procedures worldwide.As McCarthy Vet expands its portfolio through a new partnership with VETIGEL, the company remains focused on delivering the solutions today's veterinary professionals need most. This collaboration reflects its ongoing promise to bring innovative products to market that offer meaningful clinical value, ease of use, and better outcomes for patients.As a flowable hemostatic gel, VETIGEL offers veterinary surgeons a safe and efficient way to control bleeding across a wide range of surgical procedures and wound geometries